ECTE Insider Trading Activity and SEC Form 4 Filings
ECTE insider trading summary
No open-market insider purchases or sales of Echo Therapeutics, Inc. (ECTE) have been reported on SEC Form 4 in the past 12 months.
Latest ECTE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 20, 2015 | Scott Wayne Hollander | President and CEO | Buy | $12K (8,000 @ $1.48) |
| May 20, 2015 | Alan Wayne Schoenbart | CFO and Secretary | Buy | $4K (2,500 @ $1.44) |
| Jun 30, 2014 | Uri Landesman | 10% Owner | Buy | $121K (55,083 @ $2.20) |
| Jun 30, 2014 | Platinum-Montaur Life Sciences, LLC | 10% Owner | Buy | $121K (55,083 @ $2.20) |
| Jun 30, 2014 | Mark Nordlicht | 10% Owner | Buy | $121K (55,083 @ $2.20) |
| Jun 30, 2014 | Platinum Partners Liquid Opportunity Master Fund L.P. | 10% Owner | Buy | $121K (55,083 @ $2.20) |
| Jun 30, 2014 | Platinum Partners Value Arbitrage Fund, LP | 10% Owner | Buy | $121K (55,083 @ $2.20) |
| Jun 30, 2014 | Platinum Liquid Opportunity Management (NY) LLC | 10% Owner | Buy | $121K (55,083 @ $2.20) |
| Jun 30, 2014 | Platinum Management (NY) LLC | 10% Owner | Buy | $121K (55,083 @ $2.20) |
| Jun 27, 2014 | Mark Nordlicht | 10% Owner | Buy | $23K (10,656 @ $2.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.